Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran

  • Amirifard, Nasrin (Cancer Research Center, Kermanshah University of Medical Sciences) ;
  • Sadeghi, Edris (Cancer Research Center, Kermanshah University of Medical Sciences)
  • Published : 2016.05.01


Background: Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all cancers in men and less than 1% of all diagnosed breast cancers. In this study, we retrospectively evaluated the clinicopathological features, treatment options and overall survival in Kurdish MBC cases. Materials and Methods: Seventeen MBC were referred to Department of Radiation Oncology in Imam Reza Hospital, Kermanshah, Iran, between 2010 and 2016. Immunohistochemical analysis was performed for ER, PR and Her2 biomarkers and FISH for those with Her2 2+. Median follow-up period was 30 months (2-65 months). We excluded from the study patients who did not have follow-up after initial diagnosis. Treatment methods were chemotherapy, radiotherapy, hormonal therapy, target therapy and palliative care. Survival was estimated by the Kaplan Meier method (Prism 5). Results: The mean age at diagnosis was $49.24{\pm}17$ years (range, 24-85 years). Grade II was the most grade in MBC (65%). Fourteen patients (82%) had invasive ductal carcinoma, one (6%) had ductal carcinoma in situ and 2 (12%) had invasive papillary. ER, PR and Her2 were significantly positive in 14/17, 8/17 and 2/17 cases, respectively. The treatment included modified radical mastectomy for most patients. Chemotherapy with TAC and CEF regimens was delivered to 15/17 cases. Tamoxifen therapy was delivered to 14/17 cases. Three stage IV patients received Avestin and two with Her2 3+ were given Trastuzumab (Herceptin). Patients received adjuvant radiotherapy following surgery and chemotherapy. The site of metastasis was the bone in 2 cases, lung in 1 case and liver in 1 case. Zoledronic acid (Zometa) was prescribed for patients with bone metastasis. Five-year overall survival rate was 64%. Conclusions: MBC is rare. Thus, we need larger studies are in collaboration with several research centers in the field of breast cancer. ER positive, grade II of invasive ductal carcinoma, stage II and right side happened more with MBC. Overall survival is similar to other studies.


Male breast cancer;Kurdish Iran;overall survival;ER+ - PR+;Her2+;chemotherapy


Supported by : Kermanshah University of Medical Sciences


  1. Amirifard N, Sadeghi E, Payandeh M, et al (2016). Relationship between HER2 Proto-oncogene status and prognostic factors of breast cancer in the west of Iran. Asian Pac J Cancer Prev, 17, 295-8.
  2. Anders CK, Johnson R, Litton J, et al (2009). Breast Cancer Before Age 40 Years. Semin Oncol, 36, 237-49.
  3. Anderson WF, Althuis MD, Brinton LA, et al (2004). Is male breast cancer similar or different from female breast cancer?. Br Cancer Res Treat, 83, 77-86.
  4. Anderson WF, Jatoi I, Tse J, et al (2010). Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol, 28, 232-9.
  5. Cutuli B, Le-Nir CC, Serin D, et al (2010). Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 73, 246-54.
  6. Ewertz M, Holmberg L, Tretli S, et al ( 2001). Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol, 40, 467-71.
  7. Fogh S, Hirsch AE, Langmead JP, et al (2011). Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptorpositive male breast cancer. Clin Breast Cancer, 11, 39-45.
  8. Giordano SH (2005). A review of the diagnosis and management of male breast cancer. Oncologist, 10, 471-9.
  9. Giordano SH, Cohen DS, Buzdar AU ,et al (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7.
  10. Hittmair AP, Lininger RA, Tavassoli FA (1998). Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma-a preliminary report. Cancer, 83, 39-2149.
  11. Kornegoor R, Verschuur-Maes AH, Buerger H, et al (2012). Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol, 25, 398-404.
  12. La Vecchia C, Levi F, Lucchini F (1992). Descriptive epidemiology of male breast cancer in Europe. Int J Cancer, 51, 62-66.
  13. Nahleh ZA, Srikantiah R, Safa M, et al (2007). Male breast cancer in the Veterans Affairs population: a comparative analysis. Cancer, 109, 1471-77.
  14. Ravandi-Kashani F, Hayes TG (1998). Male breast cancer: a review of the literature. Eur J Cancer, 34, 1341-7.
  15. Ribeiro G, Swindell R (1992). Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer, 65, 252-54.
  16. Scott-Conner CE, Jochimsen PR, Menck HR, et al (1999). An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery, 126, 775-80.
  17. Shaaban AM, Ball GR, Brannan RA, et al (2012). A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat, 133, 949-58.
  18. Speirs V, Shaaban AM (2008). The rising incidence of breast cancer. Breast Cancer Res Treat, 115, 429-30.
  19. Tunon de Lara C, Goudy G, MacGrogan G, et al (2008). Male breast cancer: A review of 52 cases collected at the Institute Bergonie (Bordeaux, France) from 1980 to 2004. Gynecologie Obstetrique Fertilite, 36, 386-94.
  20. Willsher PC, Leach IH, Ellis IO, et al (1997). Male breast cancer: pathological and immunohistochemical features. Anticancer Res, 17, 35-2338.
  21. Xia Q, Shi YX, Liu DG (2011). Clinicopathologic characteristic of male breast cancer: analysis of 25 cases at single institution. Fang Yi Ke Da Xue Xue Bao, 31, 1469-73.
  22. Yoney A, Kucuk A, Unsal M, et al (2009). Male breast cancer: A retrospective analysis. Cancer/Radiotherapie, 13, 103-07.